The gastric motility drug market consists of prescription and over-the-counter drugs that help treat gastric motility disorders such as gastric stasis, gastroparesis and functional dyspepsia. These drugs help increase gastric emptying and stimulate gastric motility. They are used as prokinetic agents to treat symptoms of nausea, vomiting and fullness or heaviness in the stomach. The rising prevalence of gastrointestinal disorders such as diabetes has significantly increased the demand for gastric motility drugs.

The Global Gastric Motility Disorder Drug Market is estimated to be valued at US$ 83.15 Bn in 2024 and is expected to exhibit a CAGR of 5.4% over the forecast period from 2024 to 2031.

Key Takeaways

Key players operating in the gastric motility drug market include Pfizer Inc., Takeda Pharmaceutical Company Limited, Janssen Pharmaceuticals, Sun Pharmaceutical Industries Ltd., AbbVie Inc., Boehringer Ingelheim, Eli Lilly and Company, Bristol Myers Squibb, Daiichi Sankyo Company, Limited, Bausch Health Companies, Mallinckrodt Pharmaceuticals, Endo Pharmaceuticals, Eisai Co., Ltd., Ferring Pharmaceuticals, UCB, Evoke Pharma, and Cadila Pharmaceuticals. Growing geriatric population and rising incidence of diabetes as well as other diseases that affect gastric motility are fueling market growth. Technological advancements are allowing development of novel and improved treatment options for gastric motility disorders.

Market Trends

There is an increased focus on development of novel drug formulations and delivery methods for existing drugs. This includes development of advanced drug delivery systems like delayed and sustained release formulations. Drug makers are also developing new classes of prokinetic agents like ghrelin receptor agonists and 5-HT4 receptor agonists. Growing popularity of herb-based products and nutritional/dietary supplements for managing gastric motility issues naturally is also a key trend.

Market Opportunities

Emerging economies in Asia Pacific and Latin America present significant growth opportunities for players due to rising healthcare expenditures and growing patient awareness. There is scope for developing combination drug therapies involving prokinetics and other drugs for enhanced effectiveness. Further clinical research on safety and efficacy of newer compounds can help address the unmet needs of patients with severe and refractory gastric motility disorders.

The COVID-19 pandemic has significantly impacted the growth of the gastric motility disorder drug market. The lockdowns imposed across various regions led to disrupted supply chains and production schedules. With decreased access to healthcare facilities, the diagnosis and management of gastric motility disorders were also affected during the peak of the pandemic.

Prior to the pandemic, the market was growing steadily due to the rising prevalence of gastric motility disorders like gastroparesis and cyclic vomiting syndrome. The approval and launch of new drug formulations was also supporting the market expansion. However, with the onset of COVID-19, the market experienced a sudden decline in 2020 as patient visits declined and drug production was stalled. The market is gradually recovering from 2021 onwards as lockdowns are being lifted and healthcare systems are adjusting to the new normal. However, complete recovery to the pre-COVID growth levels is expected to take some more time.

Going forward, the gastric motility disorder drug market will have to focus on overcoming disruption challenges, strengthening supply chains, facilitating digital healthcare solutions, and expediting drug development programs. Supporting research on post-COVID gastrointestinal symptoms will also be crucial. Dependence on Asian countries for active pharmaceutical ingredients will need to be reduced. Overall, a coordinated response from stakeholders can help restore steady market growth over the coming years.

In terms of value, North America dominates the gastric motility disorder drug market and is expected to retain its lead position throughout the forecast period. This is attributed to factors such as the rising prevalence of disorders like gastroparesis in the region, along with high healthcare expenditures and reimbursement options. The availability of advanced treatment options has also augmented market growth in North America.

The Asia Pacific region is poised to showcase the fastest growth in the gastric motility drug market during 2024-2031. Growing awareness about gastric motility issues, increasing healthcare investments, rising income levels, expansion of drug manufacturing bases, and boom in medical tourism are some of the major factors fueling high market growth in Asia Pacific countries like India, China, and Japan. Furthermore, busy lifestyles leading to greater stress levels are contributing to the rising incidence of gastric motility disorders in Asia Pacific.

Get More Insights On This Topic: Gastric Motility Drug Market